Simonetta M. Leto

Turin, 10060, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.

Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.

Journal: Cell death & disease

Published: October 07, 2025

The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.

The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.

Journal: Cancer discovery

Published: April 18, 2024

Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 30, 2023

XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients.

XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients.

Journal: Nature communications

Published: April 26, 2023

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT).

Journal: Cell death & disease

Published: January 05, 2023

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer.

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 16, 2022

Effective drug combinations in breast, colon and pancreatic cancer cells.

Effective drug combinations in breast, colon and pancreatic cancer cells.

Journal: Nature

Published: July 02, 2021

Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer.

Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 15, 2020

HER2 activating mutations are targets for colorectal cancer treatment.

HER2 activating mutations are targets for colorectal cancer treatment.

Journal: Cancer discovery

Published: August 06, 2015

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.

Journal: Science translational medicine

Published: January 30, 2015

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 02, 2014

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies.

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: March 17, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026